Dr Sachin Shrikant Parikh, MD | |
10385 Calvert Dr, Cupertino, CA 95014-3807 | |
(650) 396-7111 | |
Not Available |
Full Name | Dr Sachin Shrikant Parikh |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 10385 Calvert Dr, Cupertino, California |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1669670592 | NPI | - | NPPES |
Mailing Address | Practice Location Address |
---|---|
Dr Sachin Shrikant Parikh, MD 10385 Calvert Dr, Cupertino, CA 95014-3807 Ph: (650) 396-7111 | Dr Sachin Shrikant Parikh, MD 10385 Calvert Dr, Cupertino, CA 95014-3807 Ph: (650) 396-7111 |
News Archive
Backers of expanding the low-income health insurance program say elected officials are turning their back on hundreds of thousands of poor Mississippi residents by refusing the federal funds that come with the expansion. Meanwhile, in Pennsylvania, insurers appear to be adding a wrinkle to Gov. Corbett's expansion plan. Also, election outcomes will play a big role in where such plans proceed.
University Hospitals Case Medical Center clinical researchers have launched an innovative clinical trial, unique in its design, which will evaluate the ability of a patient's own stem cells to prevent leg amputations in end stage peripheral arterial disease (PAD).
House Republicans on Wednesday released a list of 70 proposed budget cuts to be debated next week as Congress must vote to "fund the government past March, when the current temporary budget expires," USA Today's "On Politics" blog reports (Camia, 2/9).
For every year that a patient with diabetes takes metformin, their risk for hepatocellular carcinoma reduces, say the authors of a study that also sheds light on the cellular pathway it uses.
Biogen Idec Inc. today announced that it has increased its offer to purchase all of the outstanding shares of Facet Biotech Corporation to $17.50 per share in cash, representing an increase of $3.00 per share, or 21%, over its previous offer.
› Verified 3 days ago